A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …

Cancer is a disease caused by the accumulation of genetic and epigenetic changes in two
types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. Extensive research …

Inactivating STK11/LKB1 mutations are genomic drivers of primary resistance to
immunotherapy in KRAS-mutated lung adenocarcinoma (LUAD), although the underlying …

The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in∼ 20% of non-
small cell lung cancers (NSCLC). LKB1 is the major upstream kinase activating the energy …

Targeted therapies have demonstrated efficacy against specific subsets of molecularly
defined cancers,,,. Although most patients with lung cancer are stratified according to a …

Over the last few decades, study of cancer in mouse models has gained popularity.
Sophisticated genetic manipulation technologies and commercialization of these murine …

Importance Metformin hydrochloride is emerging as a repurposed anticancer drug.
Preclinical and retrospective studies have shown that it improves outcomes across a wide …

Glucose starvation is one of the major forms of metabolic stress in cancer cells. Deprivation
of glucose impairs glycolysis and the pentose phosphate pathway, which elicits oxidative …

Lung cancer is the leading cause of cancer-related death in men and women in the United
States, accounting for approximately 28% of total cancer deaths in 2010 despite comprising …

Inactivating mutations of the tumor suppressor gene Liver Kinase B1 (LKB1) are frequently
detected in non‐small‐cell lung cancer (NSCLC) and cervical carcinoma. Moreover, LKB1 …